"Profound Medical Corp (PROF) reported disappointing Q2 2025 earnings, with revenue falling short of estimates and an EPS of -$0.52, highlighting ongoing operational challenges. Despite some growth and innovations in prostate treatment, the overall sentiment remains cautious, reflecting investor concerns about the company's financial performance and future prospects."